Clarity Pharmaceuticals | LinkedIn (original) (raw)
``
Biotechnology Research
Sydney, NSW 9,791 followers
Clarity is developing next-generation products to address the growing need for radiopharmaceuticals in oncology.
About us
Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Sydney, NSW
Type
Public Company
Founded
2010
Specialties
Antibody and peptide imaging, Pharmaceutical imaging, Companion diagnostics, Drug development, Radiopharmaceuticals, Nuclear medicine, and Targeted therapy
Locations
Employees at Clarity Pharmaceuticals
Updates
- Clarity’s exceptional position in the radiopharmaceutical market is underpinned by its strong roots in great Australian science and dedicated team with unique expertise. These not only resulted in a pipeline of best-in-class products in clinical trials, but also laid the foundation for a number of exciting new technologies, products and indications in preclinical development, paving the way for future innovation. With a strong financial position to support its growth and the radiopharmaceutical field generating a lot of excitement, Clarity’s future has never looked brighter. Watch season 2 episode 7 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn more about what is next for Clarity and its pipeline of best-in-class products in development. #podcast #radiopharmaceuticals #biotech
- Clarity receives FDA Fast Track Designation for its diagnostic 64Cu-SAR-bisPSMA product. This designation, which is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs, provides a number of benefits in the development of 64Cu-SAR-bisPSMA, potentially reducing the New Drug Application (NDA) review time, allowing more frequent meetings with the FDA during development, and allowing Rolling Review of the planned NDA. The Fast Track Designation is supported by the initial clinical evidence suggesting that 64Cu-SAR-bisPSMA may offer improved lesion detection compared to existing prostate cancer diagnostics. It comes at a time when Clarity is actively recruiting into its first registrational Phase III trial, CLARIFY, and preparing for an End of Phase meeting with the FDA for a second pivotal Phase III trial with 64Cu-SAR-bisPSMA. Clarity is committed to advancing the development of this product to address the critical need for more accurate and accessible diagnostic tools in prostate cancer management.#biotech #radiopharmaceuticals #PSMA
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging https://www.claritypharmaceuticals.com - Clarity is committed to developing next-generation radiopharmaceuticals that provide safe and effective treatments for patients and offer a reliable, scalable and environmentally friendly solution to manufacturing and supply chain issues plaguing the current generation of products. Being able to not only develop, but also successfully deliver life changing radiopharmaceuticals to a large number of cancer patients is essential for radiopharmaceuticals to grow in the large oncology market and improve lives of people with this insidious disease. Cu-67 is produced in high quantities on electricity-powered electron accelerators, a process that is easily scalable to reach the future demand for radiopharmaceuticals globally. This is in contrast to the current process for producing Lu-177, which is reliant on an aging fleet of uranium-powered nuclear reactors that experience frequent and prolonged maintenance shutdowns, leading to shortages of these essential cancer treatments. Watch the video to learn more about the differences in the Cu-67 and Lu-177 manufacturing process and the numerous benefits the production and supply of Cu-67 can achieve.
- Radiopharmaceuticals are the next frontier in oncology, but the current generation of products is barely scratching the surface of this massive opportunity. From rolling out into new indications and diseases to combination therapies, the possibilities are endless. Driven by strong efficacy and safety data, its proprietary platform technology and numerous supply and manufacturing benefits enabled by copper isotopes, Clarity is well positioned to roll out its pipeline of radiopharmaceuticals and meet the demand for better treatments. Watch season 2 episode 5 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn about the future of radiopharmaceuticals and emerging trends in the field.
Join now to see what you are missing
Similar pages
- Telix Pharmaceuticals Limited Biotechnology Research North Melbourne, Victoria
- Fusion Pharmaceuticals Biotechnology Research Hamilton, ON
- Lantheus Pharmaceutical Manufacturing Bedford, Massachusetts
- Curium Pharma Pharmaceutical Manufacturing Paris, France
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company Biotechnology Indianapolis, Indiana
- Radiopharm Theranostics Biotechnology Research
- Actinium Pharmaceuticals, Inc. Biotechnology Research New York, NY
- Jubilant Radiopharma Pharmaceutical Manufacturing Yardley, PA
- SOFIE Pharmaceutical Manufacturing Dulles, Virginia
- Ratio Therapeutics Biotechnology Research Boston, MA
Browse jobs
- Sales Director jobs 1,528 open jobs
- Emergency Manager jobs 473 open jobs
- Chemist jobs 614 open jobs
- Project Manager jobs 9,839 open jobs
- Vice President Marketing jobs 81 open jobs
- Project Management Specialist jobs 4,580 open jobs
- Medical Sales Representative jobs 187 open jobs
- Territory Sales Manager jobs 2,152 open jobs
- Head of Sales jobs 1,311 open jobs
- Scientist jobs 706 open jobs
- Commercial Manager jobs 4,463 open jobs
- Senior Data Engineer jobs 1,875 open jobs
- Analyst jobs 17,686 open jobs
- Associate Project Manager jobs 463 open jobs
- Director jobs 35,133 open jobs
- Senior Director jobs 3,971 open jobs
- Account Executive jobs 3,175 open jobs
- Sales Engineer jobs 3,829 open jobs
- Account Manager jobs 4,552 open jobs
- Biostatistician jobs 676 open jobs